Meeting
2019 ASCO Annual Meeting
Intra and perinodular CT delta radiomic features associated with early response to predict overall survival (OS) in immunotherapy-treated non-small cell lung cancer (NSCLC): A multi-site multi-agent study.
Authors
Prateek Prasanna
Case Western Reserve University, Cleveland, OH
Prateek Prasanna , Mohammadhadi Khorrami , Amit Gupta , Pradnya Dinkar Patil , Monica Khunger , Priya Velu , Kaustav Bera , Mehdi Alilou , Vamsidhar Velcheti , Anant Madabhushi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2588)
DOI
10.1200/JCO.2019.37.15_suppl.2588
Abstract #
2588
Poster Bd #
232
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2022 ASCO Annual Meeting
Pan-cancer (ca) analysis of the safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) living with HIV (PLWH): Results from the international CATCH-IT consortium.
First Author: Talal El Zarif
Poster
2020 ASCO Virtual Scientific Program
CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC).
First Author: Erica C. Nakajima
Poster
2018 ASCO Annual Meeting
Diffusion of innovation in oncology: A case study of immuno-oncology (IO) adoption for advanced non-small lung cancer (aNSCLC) patients across practices in the US.
First Author: Caroline Savage Bennette